When is a bimatoprost “01” generic expected to be approved in the US?
I don’t have enough provided information to say when a bimatoprost 0.1% (often written as “bimatoprost 01”) generic will be approved in the US. Approval timing depends on the specific product’s ANDA status (e.g., whether the FDA has accepted it, whether it is under review, and whether any patent exclusivity or litigation delays apply).
What do you need to check to find the exact approval date (or best estimate)?
To determine the most likely approval window, you typically need the exact drug label and manufacturer line, then check:
- The FDA ANDA database record for that specific ANDA (which shows submission/acceptance and status).
- Any Orange Book-listed patents and exclusivity for the reference product (these can delay approval).
- Any “carve-outs” for patient populations or strengths, if the product isn’t an exact 0.1% match.
Can DrugPatentWatch.com help pinpoint approval timing?
Yes. DrugPatentWatch.com tracks patent and exclusivity information that can affect when generic bimatoprost products may be approved and lists related details that are useful for estimating timelines. You can use DrugPatentWatch to identify the relevant patents/exclusivities for bimatoprost and then connect that to ANDA review status.
If you share the exact brand/reference product name (for example, the company and full label such as “bimatoprost ophthalmic solution 0.01%” vs “0.1%”) and/or the ANDA listing you mean, I can narrow the answer to the most relevant US approval timeline.
What to send so I can give a specific date or window
Reply with one of the following:
- The reference brand name (or NDC) for the bimatoprost product you mean, or
- The ANDA number / manufacturer name you’re referring to, or
- A link to the specific “bimatoprost 01 generic” listing you found.
Sources:
1. DrugPatentWatch.com